Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
doi: 10.1111/tra.12707, 148
MBX 4291, dual GLP-1/GIP co-agonist prodrug designed for potential once-monthly dosing and improved tolerability in obesity Recent Highlights: In June 2026, MBX Biosciences announced data that demonstrated sustained benefit of its once-weekly Canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism
Psychoneuroendocrinology , 38 (9), 16981708
In both studies, tesamorelin-treated patients completing the 26-week treatment period were re-randomized to blinded therapy with either daily placebo or 2 mg tesamorelin for an additional 26-week treatment period (Extension Phase) in order to assess maintenance of VAT reduction and to gather long-term safety data
The reconstitution solvent, typically bacteriostatic water, is slightly acidic, which is generally favorable for stability
US$ 21.95
US$ 28.07
.svg)
US$ 26.44
US$ 24.43
